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Background: Adherence to pharmacological therapy is a complex and multifactorial issue 
that can substantially alter the outcome of treatment. Especially when using long-term medica-
tion, cancer patients have adherence rates similar to those of patients with other diseases. The 
consequences of poor adherence are poor health outcomes and increased health care costs. Only 
few studies have focused on the use of oral anticancer agents in daily practice. Information 
about the reasons for nonadherence is essential for the development of interventions that may 
improve adherence. This report presents the CAPER-capecitabine protocol, which is designed 
to study the adherence to capecitabine and the influence of patient attitudes towards medication 
and self-reported side effects. Furthermore, the relationships between patient characteristics, 
disease characteristics, side effects, quality of life, patient beliefs and attitudes towards disease 
and medication, dose adjustments, reasons for discontinuation, and plasma concentration of three 
of the main metabolites, including the active compound 5-fluorouracil, will be explored.
Methods: In this multicenter, prospective, observational cohort study, 90 patients aged 18 years 
or older starting treatment with capecitabine will be included and followed for a period up to 
five cycles. The main study parameters are adherence, patient attitudes towards medication, 
and the number and grade of patient-reported side effects. At baseline and during week 2 of 
cycles 1, 3 and 5, patients will be asked to donate blood and fill out a questionnaire. Blood 
samples will be analyzed for plasma concentration of the metabolites, 5′-deoxy-5-fluorouridine, 
5-fluorouracil, and α-fluoro-β-alanine. The CAPER-capecitabine trial is closely related to the 
CAPER-erlotinib trial.
Discussion: The aim of the present study is to get more insight into patient experiences with 
the use of capecitabine in daily practice and the various aspects that govern adherence. We 
hypothesize that patient attitudes towards medication and the side effects experienced play an 
important role in the way patients use capecitabine. We expect that our findings will be use-
ful for health care professionals in developing interventions to support patients in improving 
adherence and persistence with the use of capecitabine.
Keywords: capecitabine, medication adherence, patients’ experiences, medical oncology, oral 
antineoplastic agents
Background
Intravenous administration is an important route for pharmacological treatment of 
cancer. Over the last decade, a growing number of oral substances have been intro-
duced in cancer treatment. Most patients prefer oral use of anticancer agents as long 
as it does not compromise the outcome of treatment.1–3 In addition, the overall costs 
of oral treatment are often lower than those of intravenous therapy.4–6 However, with 
the use of oral medication at home, the issue of adherence needs to be considered.
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Adherence
Adherence to oral pharmacological therapy is a complex and 
multifactorial issue that can substantially alter the outcome 
of therapy.7,8 Adherence (synonymous with compliance) 
has recently been defined by the International Society for 
Pharmacoeconomics and Outcome Research as the extent 
to which a patient acts in accordance with the prescribed 
interval and dose of a drug regimen.9 A patient is optimally 
adherent if no doses are missed, no extra doses are taken, 
and no doses are taken in the wrong quantity or at the wrong 
time. Adherence is measured over a period of time and 
reported as the adherence rate, which is the percentage of 
dose taken in relation to what was prescribed.10 There are 
several methods used to measure adherence, including self-
reports, pill counts, electronic monitoring systems, analyses 
of pharmacy dispensing records, and assessment of blood 
or urine samples. There is no golden standard measurement 
and all methods have limitations.10,11 The major limitation 
of measuring adherence is the so-called Hawthorne effect, 
ie, the monitoring of adherence itself influences adherence, 
because the awareness of patients that adherence is being 
monitored may influence their behavior. Adherence rates 
for many chronic drug therapies range between 35% and 
70%.7,12 The consequences of poor adherence are poor health 
outcomes and increased health care costs.7
Adherence in oncology
Cancer patients are generally thought to have higher adher-
ence rates than other patients because they are highly moti-
vated by the gravity of their disease.13,14 However, cancer 
patients appear to have similar adherence rates to those of 
patients with other diseases.10,15,16 Treatment duration plays 
a role in adherence to the regimen. When the medication is 
continued over a longer period of time, patients become less 
adherent.17 The measurement of adherence with medication 
that is used in complex cyclic schedules with stop periods 
and many individual adjustments during treatment, as often 
occurs in oncology, is challenging, since this is more dif-
ficult than the measurement of medication used on a regular 
daily basis.
In oncology, adherence has been studied mainly in two 
subpopulations, both using long-term medication. In the 
first population, adherence of patients with breast cancer to 
adjuvant hormonal therapy has been the subject of several 
studies.10 Reported adherence rates range from 50% to 
98%.14,17,18 Several studies concerning adherence with oral 
medication have been published in the second population, 
being patients with chronic myeloid leukemia.16,19,20 
Nonadherence has been associated with a poorer response 
to imatinib.16,19 Noens et al have shown that patients with 
a suboptimal response had higher percentages of imatinib 
not taken (23%) than those with optimal response (7%).16 
Marin et al have also demonstrated that there was a strong 
correlation between adherence rate and response in patients 
with chronic myeloid leukemia.19 Adherence was the only 
critical factor for achieving a molecular response. The results 
of these studies cannot be translated directly to adherence 
with other oral anticancer drugs, because their use differs 
mainly with respect to duration of treatment and the toxicity 
generated by the treatment.
Another frequently overlooked problem is over adherence, 
which may be more an issue in oncology than in other dis-
eases and may lead to substantially increased toxicity.11 In 
the study by Nilsson et al, 30% of cancer patients had an 
oversupply of their medication.15
Medical oncologists and hematologists may not always 
consider the issue of adherence. As yet, suboptimal adher-
ence may prove to be the greatest barrier to the efficacy of 
the various newly introduced oral anticancer agents.10,19
Causes of nonadherence
Several factors are associated with nonadherence. These 
include patient variables, such as demographic factors and 
patients’ beliefs, and disease variables, various aspects of 
treatment regimens, side effects, and quality of life.
The commonsense model of self-regulation developed 
by Leventhal et al21 is a theoretical model for understanding 
patient perceptions of illness.22 According to the com-
monsense model of self-regulation, patient perception of 
and beliefs about their illness are important factors in their 
reactions and behavior to health threats. Illness perceptions 
can easily be measured with the Brief Illness Perceptions 
Questionnaire.23 Another factor which has been shown to 
influence adherence is patient beliefs about the medication, 
often measured with the Beliefs about Medicines 
Questionnaire (BMQ).24
Few studies have focused on patients’ reasons for not 
adhering to oral anticancer agents. Eliasson et al have 
reported that finding ways to deal with side effects leads to 
better adherence in patients with chronic myeloid leukemia.25 
In clinical trials, adverse events are generally reported by 
clinicians using, eg, the National Cancer Institute Common 
Terminology Criteria for Adverse Events.26 Basch et al 
have shown the value of patient-reported adverse events 
in cancer patients, which better reflect their daily health 
status.27–29
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Capecitabine
Capecitabine (Xeloda®) is an oral anticancer agent, which 
was introduced in 2001. Capecitabine is an oral prodrug for 
5-fluorouracil (5-FU). It is one of a number or oral formula-
tions of 5-FU (UFT, S-1, doxifluridine, capecitabine) which 
were developed to mimic continuous infusions (defined as 
one week or longer), which are associated with longer sur-
vival than the commonly used intravenous bolus administra-
tion schedules (eg, the Roswell Park and Mayo schedules).30,31 
These schedules were standard until early 2000. Continuous 
administration of 5-FU leads to prolonged exposure to low 
concentrations of 5-FU which has been shown both in vitro 
and in vivo to be more effective than short exposure to high 
concentrations. Capecitabine is registered in Europe for the 
treatment of advanced colorectal cancer, gastric cancer, and 
breast cancer.32 It is also registered for the adjuvant treatment 
of patients following surgery of stage III (Dukes’ stage C) 
colon cancer, either given alone or combined with either 
oxaliplatin or irinotecan. Capecitabine is commonly used in a 
3-week treatment cycle, with an intake of capecitabine twice 
daily for 14 days followed by a 7-day rest period.
The most common side effects of capecitabine are gas-
trointestinal disorders (especially diarrhea, nausea, vomit-
ing, abdominal pain, and stomatitis), hand-foot syndrome 
(palmar-plantar erythrodysesthesia), fatigue, asthenia, 
anorexia, cardiotoxicity, increased renal dysfunction in 
those with pre-existing compromised renal function, and 
thrombosis/embolism.32
Several studies have demonstrated that capecitabine is as 
effective as intravenous 5-FU. Borner et al have reported in a 
crossover study showing that patients preferred oral capecit-
abine to intravenous 5-FU.3 However, using a similar study 
design, Pfeiffer et al observed that patients prefer the regimen 
with the lowest toxicity and that the route of administration 
is of minor importance.33 The use of capecitabine has also 
been the subject of pharmacoeconomic analyses. Several 
studies have shown the cost-effectiveness of treatment with 
capecitabine as compared with that of 5-FU in patients with 
colorectal cancer or compared with intravenous taxane-based 
therapy in patients with breast cancer.34–36
Adherence with capecitabine has been the subject of a 
few studies. In a review published by Ruddy et al, only one 
study concerning adherence with capecitabine was includ-
ed.10 Partridge et al reported at the 2008 American Society 
of Clinical Oncology annual meeting that 76% of 161 
breast cancer patients took at least 80% of their prescribed 
capecitabine doses, as measured by an electronic monitor-
ing system during a six-cycle period.37 Winterhalder et al 
assessed adherence to capecitabine with self-reporting in 
diaries.38 They observed that 91% of patients were adherent 
with all doses. A similar rate has been reported by Simons 
et al using an electronic monitoring system.39
Pharmacokinetics
Capecitabine is rapidly and extensively absorbed through the 
gastrointestinal wall as an intact molecule, and rapidly meta-
bolized to 5-FU via a three-step enzymatic cascade. First, 
it is metabolized to 5′-deoxy-5-fluorocytidine (5′-DFCR), 
thereafter to 5′-deoxy-5-fluorouridine (5′-DFUR), and 
subsequently to the active compound 5-FU. 5-FU is metabo-
lized to dihydrofluorouracil, 5-fluoro-ureido-propionic 
acid, and α-fluoro-β-alanine (FBAL, see Figure 1).40 When 
taken with food at a dose of 1250 mg/m2 on day 14, peak 
plasma concentrations (C
max
) of capecitabine, 5′-DFCR, 
5′-DFUR, 5-FU, and FBAL are 4.7, 3.1, 12.1, 1.0, and 
5.5 µg/mL, respectively. Peak plasma concentrations are 
reached approximately 1.5–3.5 hours after administration. 
The elimination half-life (t
1/2
) of capecitabine and its metabo-
lites in plasma is short, ie, 1–3 hours.32
There is considerable variability in the plasma concen-
trations of capecitabine and its metabolites.41 However, it 
should be realized that activation to 5-FU takes place in the 
tumor. The enzyme involved in the final conversion to 5-FU 
(thymidine phosphorylase), is found in tumor tissues, but 
also in normal tissues, albeit usually at lower levels; 5-FU 
concentrations in plasma can be considered as a reflection of 
the release from tumors and not as a reliable pharmacokinetic 
parameter for capecitabine. Moreover, it has been demon-
strated that 5-FU has a relatively long tissue half-life, both in 
animal systems and in patients.42 With use at home, variations 
in plasma concentration may also be influenced by adherence 
with capecitabine. It is hypothesized that a higher adherence 
rate will lead to higher plasma concentrations which, in turn, 
may lead to better survival rates.
Intake of food prior to or together with administration 
of capecitabine results in a longer time taken to reach peak 
plasma concentrations and a lower C
max
 of capecitabine and 
its metabolites. The manufacturer advises in the European 
Public Assessment Report that “the tablets should be 
swallowed with water within the 30 min after a meal”.32,43 
Renal impairment has no effect on the pharmacokinetics of 
capecitabine or 5-FU, but leads to an increased exposure of 
5′-DFUR and FBAL and therefore requires dose modification 
of capecitabine.44 Twelves et al have reported that plasma 
concentrations of capecitabine, 5′-DFUR, 5-FU, and FBAL 
were, in general, higher in patients with liver dysfunction, 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
743
Adherence with capecitabine in daily practice
Patient Preference and Adherence 2012:6
while the opposite was found for 5′-DFCR.45 There were no 
clinical relevant differences in the adverse effects between 
patients with and without hepatic dysfunction.
Ethnicity may also influence the pharmacokinetics of 
capecitabine and its metabolites. In Caucasian patients, 
higher plasma concentrations of FBAL were measured than 
in Japanese patients.46
Genetic factors may affect the efficacy and toxicity of 
capecitabine related to the activity of the enzymes involved in 
its metabolism. Mutations and polymorphisms in dihydropy-
rimidine dehydrogenase, resulting in decreased degradation of 
5-FU (from capecitabine) is associated with severe toxicity.47–49 
Other mutations and polymorphisms may result in altered 
activity of cytidine deaminase or carboxylesterase, thereby 
influencing the efficacy and toxicity of capecitabine.50,51
A small increase in plasma concentration of capecitabine 
and 5′-DFCR may occur when given concurrently with an 
antacid containing aluminum or magnesium hydroxide. This 
has not been shown for 5′-DFUR, 5-FU, and FBAL.52
The various factors described above have to be taken into 
account when the relationship between plasma concentrations 
and adherence rates is studied in patients using capecitabine. 
The mutations and polymorphisms will not be evaluated in 
the present study, but may be part of future research.
Several studies on the efficacy, side effects, and pharma-
cokinetics of capecitabine have shown that plasma concen-
trations of 5′-DFUR, 5-FU, and FBAL are related to efficacy 
and toxicity. Gieschke et al have observed that the C
max
 of 
5′-DFUR was positively associated with survival and that 
the area under the concentration-time curve (AUC) of 5-FU 
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Figure 1 Metabolic pathways for capecitabine and tegafur. (A) Capecitabine is converted into active metabolite in situ by thymidine phosphorylase or uridine phosphorylase. 
Further 5-fluorouracil catabolism is initiated by dihydropyrimidine dehydrogenase, eventually yielding FBAL, a catabolite implicated in the etiology of hand-foot syndrome. 
(B) Tegafur is activated by cytochrome P450 2A6, forming 5-hydroxytegafur, an unstable intermediate which spontaneously converts to 5-fluorouracil.
Reprinted by permission from Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? 
Clin Cancer Res. 2008;14:8–13.
Abbreviations: FBAL, and α-fluoro-β-alanine; 5′-dFUR, 5′-deoxy-5-fluorouridine; FUPA, 5-fluoro-ureido-propionic acid; 5′-dFCR; 5′-deoxy-5-fluorocytidine.
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was negatively associated with time to disease progression.53 
This is in contrast with data on 5-FU in which a higher AUC 
of 5-FU was associated with a longer survival.54 In general, 
in 5-FU administration schedules, a clear relationship was 
found for the AUC of 5-FU and both hematological and gas-
trointestinal toxicity.55,56 In patients with grade 3–4 diarrhea, 
the AUC of FBAL was proportionately increased. Grade 3–4 
hyperbilirubinemia was positively associated with the AUC 
of 5-FU and negatively associated with the C
max
 of FBAL.57 
Plasma concentrations of capecitabine and 5′-DFCR were 
not related to toxicity.53
Capecitabine can cause hand-foot syndrome, which is 
most likely associated with accumulation of the breakdown 
product FBAL, given that in formulations in which 
dihydropyrimidine dehydrogenase is inhibited, no hand-
foot syndrome was observed.40 Because side effects may 
be a reason for nonadherence, the plasma concentrations of 
5′-DFUR, 5-FU, and FBAL are analyzed in this study.
The primary objective in this study is adherence in 
patients with cancer starting capecitabine and the  influence 
of patients’ attitudes and side effects on adherence. The 
second part of this study contains a validation study of 
the adherence measurements and an explorative study on 
the relationships between the following parameters: patient 
characteristics, disease characteristics, side effects,  quality 
of life, patients’ beliefs and attitudes towards disease 
and medicines, adherence, dose adjustments, and plasma 
5′-DFUR, 5-FU, and FBAL concentrations.
Materials and methods
Study design
This is a prospective observational multicenter cohort study 
in which cancer patients starting on treatment with capecit-
abine will be followed for up to five 3-weekly cycles. The 
trial will end when the last patient has been followed for 
five cycles. The CAPER-capecitabine trial (NTR2324) is 
closely related to the CAPER-erlotinib trial (NTR1830) 
which is being performed simultaneously.58 The protocol 
was approved by the medical ethics review board of the VU 
University Medical Center, Amsterdam, The Netherlands.
Recruitment and consent
Patients are to be recruited by the departments of medi-
cal oncology from 10 hospitals in The Netherlands. After 
a patient and physician have decided on treatment with 
capecitabine, the patient will be informed about the study and 
receive written information to take home. Within 2 days, the 
researcher contacts the patient by phone to inform him/her 
further about the study and to ask for his/her consent. The 
patient will be asked to sign the informed consent form.
Inclusion criteria
Patients on treatment in one of the participating hospitals 
starting with the use of capecitabine can be included. Patients 
younger than 18 years and those with insufficient knowledge 
of the Dutch language are excluded. According to the sample 
size calculation (see Statistical analysis) a total number of 
90 patients are to be enrolled.
Measurements
Several methods are used to determine the variables. Most 
information is collected directly from patients, ie, they 
will fill out questionnaires and donate blood samples. 
Furthermore, medical information is retrieved from the 
patients’ file.
Questionnaires
Patients will be asked to fill out four questionnaires spread 
over a 14-week period. The first questionnaire (t = 0) con-
tains questions about patient characteristics, comedication, 
side effects, quality of life, and patients’ beliefs and attitude 
towards disease and medication. In week 2 of cycles 1, 
3 and 5, patients are asked to fill out an elaborate question-
naire containing questions determining the adherence behav-
ior, side effects, dose adjustment, comedication, quality of 
life, and their beliefs and attitude towards the disease and 
medication. Discontinuation and reasons for discontinuation 
are to be canvassed in a short questionnaire when a patient 
discontinues capecitabine treatment prematurely.
The questionnaires include the following items:
•	 The MARS (Medication Adherence Report Scale) 
questionnaire59,60 contains statements about adherence 
behavior, and the nature and grade of patient-reported 
side effects on a five-point scale.
•	 Quality of life measured with the Short Form (SF)-12 
Health Survey.61,62 The SF-12 is a short version of the 
SF-36 and is a validated method for measurement of 
quality of life.
•	 Attitude towards disease is measured using the Brief 
Illness Perception Questionnaire.23 The Brief Illness 
 Perception Questionnaire is a validated method measuring 
attitudes towards disease.
•	 Beliefs and attitudes towards medicines are measured 
with the validated BMQ questionnaire.24 The BMQ is 
divided into two parts, ie, the BMQ general and the BMQ 
specific. The BMQ general measures patient beliefs and 
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attitudes towards medicines in general, whereas the BMQ 
specific is specific for capecitabine.
•	 Patient characteristics, ie, date of birth, gender, and 
socioeconomic status.
•	 Dose adjustments by the patient, with dose adjustments 
introduced by the physician to be derived from the 
patient file.
•	 Comedication.
•	 Discontinuation and reasons for discontinuation. 
Discontinuation will also be determined from the 
patient file.
Patient file
The following items are derived from the patient treat-
ment file:
•	 Disease characteristics, including disease stage and line 
of treatment
•	 Dose adjustments
•	 Discontinuation and reasons for discontinuation.
Patient files-pharmacy records-pill count method
This pill count method will take into account the cyclic dosing 
regimen with stop periods and individual adjustments made 
by the physician, such as postponing a cycle or dose changes. 
Patients will be contacted by the researcher by telephone to 
count their remaining pills at that moment. The dispensing 
records of the pharmacies used by the patient will be assessed. 
Patients will be asked whether they have returned pills at the 
pharmacy or disposed of pills in any other way. The actual 
number of pills used will be calculated from this informa-
tion (dispensings minus adjustments minus pill count) and 
compared with the prescribed number of pills, as registered in 
the patient’s medical file, to calculate the adherence rate.
Blood samples
Before the start of treatment with capecitabine, baseline blood 
samples are collected. In the second week of cycles 1, 3, and 5, 
blood samples are collected. At these visits, patients are asked 
when they ate their last meal and at what time they took their 
last capecitabine medication. The timing of collection of the 
blood sample will be recorded. The blood samples will be 
analyzed for plasma concentrations of 5′-DFUR, 5-FU, and 
FBAL using a validated liquid chromatography/tandem mass 
spectrometry method. Capecitabine is most commonly used in 
a 3-week treatment cycle, with an intake of capecitabine twice 
daily for 14 days followed by a 7-day rest period.32 In the event 
of a longer rest period, the number of additional rest days will 
be added to the schedule to make sure the measurements always 
take place in the second week of each cycle.
Statistics
The primary determinant of interest is patient attitudes 
towards anticancer drugs at the start of therapy. We will test 
the hypothesis that the probability of nonadherence does not 
differ between those with a negative attitude and those with 
a positive attitude towards capecitabine, against the one-
sided alternative that nonadherence is higher in those with a 
negative attitude. Based on previous studies, the percentage 
of patients who are nonadherent with drug therapy is esti-
mated at 35% for patients with a negative attitude towards 
capecitabine, and at 10% for patients with a positive attitude 
towards capecitabine. To test the hypothesis at a significant 
level of 0.05, we need 33 patients with a positive attitude and 
33 patients with a negative attitude to achieve 80% power. 
To reach the required number of evaluable patients, a total 
number of 90 patients will be included in the study. The 
statistical analyses will be performed using SPSS version 
20.0 (SPSS Inc, Chicago, IL).
Discussion
The present study aims to obtain more insight into patient 
experiences with the use of capecitabine in daily practice. 
We expect variability in adherence among the general 
oncology population. This may be complicated by interpa-
tient variability in pharmacokinetics. We hypothesize that 
patient attitudes towards anticancer drugs and side effects 
experienced play an important role in the way patients use 
capecitabine. Therefore, the relationship between attitude, 
self-reported side effects, and adherence is also defined as 
a main objective. To obtain more insight into other factors 
related to adherence and other aspects of use at home, the 
effects of the determinants are studied in an explorative 
manner. We expect that the present study will provide 
valuable knowledge on patient experiences with the use of 
capecitabine. This knowledge will be useful for health care 
professionals to develop specific interventions to support 
patients with the use of capecitabine in order to derive optimal 
benefit from the medication.
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